Herpes simplex virus zosteriform lesions with adoptive transfer of immune cells: A murine model which mimics human recurrent disease

Antiviral Research

Volumn 38, Issue 1, 1998, Pages 43-53

  Awan, Aftab R ^a   Harmenberg, Johan ^c   Kristofferson, Ann ^b   Field, Hugh J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Infection and Immunity   (Sweden)

^c MEDIVIR AB   (Sweden)

Author keywords

Antiviral; Foscarnet; Herpes; Immune cells; Topical; Virus

Indexed keywords

FOSCARNET;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CERVICAL LYMPH NODE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; HERPES; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; TARGET ORGAN; TOPICAL DRUG ADMINISTRATION; TOPICAL TREATMENT; VIRUS REPLICATION;

ADMINISTRATION, TOPICAL; ADOPTIVE TRANSFER; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; DISEASE MODELS, ANIMAL; EAR; FEMALE; FOSCARNET; HERPES SIMPLEX; HUMANS; MICE; MICE, INBRED BALB C; RECURRENCE;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; MURINAE; PINNA; SIMPLEXVIRUS;

EID: 0032053632     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00003-5     Document Type: Article

References (49)

1. Awan, A.R., Harmenberg, J., Flink, O., Field, H.J., 1998. Combinations of antiviral and anti-inflammatory preparations for the topical treatment of herpes simplex virus assessed using a murine zosteriform infection model. Antiviral Chem. Chemother. 9, 19-24.
2. Baringer, J.R., Swoveland, P., 1973. Recovery of herpes simplex virus from human trigeminal ganglions. New Engl. J. Med. 288, 648-650.
3. Barton, S.E., Munday, P.E., Kinghorn, G.R., Van der Meijden, W.I., Stolz, E., Notowicz, A., Rashid, S., Schuller, J.L., Essex-Cater, A.J., Kuipers, M.H.M., Ghanas, A.C., 1986. Topical treatment of recurrent genital herpes simplex virus infection with trisodium phophonoformate (foscarnet): double-blind, placebo controlled multicentre study. Genitourin. Med. 62, 247-250.
4. Blatt, A.N., Laycock, K.A., Brady, R.H., Traynor, P., Krogstad, D.J., Pepose, J.S., 1993. Prophylactic acyclovir effectively reduces herpes simplex virus type 1 reactivation after exposure of latently infected mice to ultraviolet B. Invest. Ophthalmol. Vis. Sci. 34, 3459-3469.
5. Blyth, W.A., Harbour, D.A., Hill, T.J., 1984. Pathogenesis of zosteriform spread of herpes simplex virus in the mouse. J. Gen. Virol. 65, 1477-1486.
6. Douglas, J.M., Critchlow, C., Benedetti, J., Mertz, G.J., Conner, J.D., Hintz, M.A., Fahnlander, A., Remington, M., Winter, C., Corey, L., 1984. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. New Engl. J. Med. 310, 1551-1556.
7. Field, H.J., Tewari, D., Sutton, D., Thackray, A.M., 1995. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob. Agents Chemother. 39, 1114-1119.
8. Field, H.J., Bell, S.E., Elion, G.B., Nash, A.A., Wildy, P., 1979. Effect of acycloguansosine treatment on acute and latent herpes simplex infection in mice. Antimicrob. Agents Chemother. 15, 554-561.
9. Harbour, D.A., Hill, T.J., Blyth, W.A., 1983. Recurrent herpes simplex in the mouse: inflammation in the skin and activation of virus in the ganglia following peripheral stimulation. J. Gen. Virol. 64, 1491-1498.
10. Hendricks, R.L., Tumpey, T.M., 1990. Contribution of virus and immune factors to herpes simplex virus type 1, induced corneal pathology. Invest. Ophthalmol. Vis. Sci. 31, 1929-1939.
11. Hill, T.J., 1985. Herpes simplex virus latency. In: Roizman, B. (Ed.), The Herpesviruses, vol. 3. Plenum, New York, pp. 175-240.
12. Hill, T.J., Blyth, W.A., Harbour, D.A., 1978. Trauma to the skin causes recurrence of herpes simplex in the mouse. J. Gen. Virol. 39, 21-28.
13. Hill, T.J., Blyth, W.A., Harbour, D.A., 1983. Recurrence of herpes simplex in the mouse requires an intact nerve supply to the skin. J. Gen. Virol. 64, 2763-2765.
14. Hill, T.J., Blyth, W.A., Harbour, D.A., Tullo, A.B., Easty, D.L., Shimeld, C., 1984. Antiviral agents, anti-inflammatory agents and models of herpes simplex in the mouse. In: Rapp, F. (Ed.), Herpesvirus. Alan R. Liss, New York, pp. 601-615.
15. Hill, T.J., Field, H.J., Blyth, W.A., 1975. Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. J. Gen. Virol. 28, 341-353.
16. Juel-Jensen, B.E., MacCallum, F.O., 1964. Treatment of herpes simplex lesions of the face with idoxuridine: results of a double-blind controlled trial. Br. Med. J. 2, 987-988.
17. Kapoor, A.K., Nash, A.A., Wildy, P., Phelan, J., McLean, C.S., Field, H.J., 1982. Pathogenesis of herpes simplex congenitally athymic mice: the relative roles of the cell mediated and humoral immunity. J. Gen. Virol. 60, 225-233.
18. Kristofferson, A., Ericson, A.C., Sohl -Åkerlund, A., Datema, R., 1988. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. J. Gen. Virol. 69, 1157-1166.
19. Mclennan, J.L., Darby, G., 1980. Herpes simplex virus latency: the cellular location of virus in dorsal root ganglia and the fate of the infected cells following virus activation. J. Gen. Virol. 51, 233-243.
20. Myers, R.I., Pettit, T.H., 1973. The pathogenesis of corneal inflammation due to herpes simplex virus 1 : corneal hypersensitivity in the rabbit. J. Immunol. 111, 1031-1042.
21. Nagafuchi, S., Oda, H., Mori, R., Taniguchi, T., 1979. Mechanism of acquired resistance to herpes simplex virus infection as studied in nude mice. J. Gen. Virol. 44, 715-723.
22. Nahmias, A.J., Keyserling, H., Lee, F.K., 1989. Herpes simplex viruses 1 and 2. Viral Infections of Humans. Plenum, New York, pp. 393-417.
23. Nash, A.A., Wildy, P., 1983. Immunity in relation to the pathogenesis of herpes simplex virus. In: Ennis, F.A. (Ed.), Human Immunity to Viruses. Academic Press, New York, pp. 179-192.
24. Nash, A.A., Field, H.J., Quartey-Papafio, R., 1980a. Cell mediated immunity in herpes simplex virus infected mice: induction, characterisation and antiviral effects of delayed type hypersensitivity. J. Gen. Virol. 48, 351-357.
25. Nash, A.A., Quartey-Papafio, R., Wildy, P., 1980b. Cell mediated immunity in herpes simplex virus infected mice: functional analysis of lymph node cells during periods of acute and latent infection with reference to cytotoxic and memory cells. J. Gen. Virol. 49, 309-317.
26. Nash, A.A., Phelan, J., Wildy, P., 1981. Cell mediated immunity in herpes simplex infected mice: H-2 mapping of the delayed type hypersensitivity response and the antiviral T cell response. J. Immunol. 26, 1260-1262.
27. Niemialtowski, M.G., Rouse, B.T., 1992. Phenotypic and functional studies on ocular T cells during herpetic infectious of the eye. J. Immunol. 148, 1864-1870.
28. Openshaw, H., Asher, L.V.S., Wohlenberg, T., Sekizawa, T., Notkins, A.L., 1979. Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation. J. Gen. Virol. 44, 205-215.
29. Perna, J.J., Mannix, M.L., Rooney, J.F., Notkins, A.L., Straus, S.E., 1987. Reactivation of latent herpes simplex virus infection by ultraviolet light: a human model. J. Am. Acad. Dermatol. 17, 473-478.
30. Roizman, B., Sears, A.E., 1990. Herpes simplex viruses and their replication. In: Fields, B.N., et al. (Eds.), Virology 2nd ed. Raven Press, New York, pp. 1795-1841.
31. Sacks, S.L., Portnoy, J., Lawee, D., Slech, W., Aoki, F.Y., Tyrrell, D.L., Poisson, M., Bright, C., Kaluski, J. and the Canadian Co-operative Study Group, 1987. Clinical course of recurrent genital herpes and treatment with foscarnet cream; results of Canadian multicenter trial. J. Infect. Dis. 155, 178-186.
32. Sawtell, N.M., Thompson, R.L., 1992a. Rapid in vivo rectivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J. Virol. 66, 2150-2156.
33. Sawtell, N.M., Thompson, R.L., 1992b. Herpes simplex virus type 1 latency-associated transcription unit promote anatomical site-dependent establishment and reactivation from latency. J. Virol. 66, 2157-2169.
34. Shimeld, C., Whiteland, J.L., Williams, N.A., Easty, D.L., Hill, T.J., 1996a. Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: an in vivo study of virus antigen and immune cell infiltration. J. Gen. Virol. 77, 2583-2590.
35. Shimeld, C., Whiteland, J.L., Nilcholls, S.M., Easty, D.L., Hill, T.J., 1996b. Immune cell infiltration in corneas of mice with recurrent herpes simplex virus disease. J. Gen. Virol. 77, 977-985.
36. Simmons, A., Nash, A.A., 1984. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the roles of immune cells in prevention of recurrent disease. J. Virol. 52, 816-821.
37. Spruance, S.L., 1988. Cutaneous herpes simplex virus lesions induced by ultraviolet radiation. Am. J. Med. 85 (Suppl. 2A), 43-45.
38. Spruance, S.L., 1992. The natural history of recurrent oral-facial herpes simplex virus infection. Semin. Dermatol. 11, 200-206.
39. Spruance, S.L., Crumpacker, C.S., Schnipper, L.E., Kern, E.R., Marlowe, S., Arndt, K.A., Overall, J.C. Jr., 1984. Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrob. Agents Chemother. 25, 553-555.
40. Spruance, S.L., Rea, T.L., Thoming, C., Tucker, R., Saltzman, R., Boon, R., 1997. Penciclovir cream for the treatment of herpes simplex labialis: a randomized multicenter, double-blind, placebo-controlled trial. J. Am. Med. Assoc. 277, 1374-1379.
41. Spruance, S.L., Stewart, J.C.B., Freeman, D.J., et al, 1990. Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: a multicenter placebo-controlled trials. J. Infect. Dis. 161, 191-197.
42. Spruance, S.L., Freeman, D.J., Seth, N.V., 1986. Comparison of topical foscarnet, acyclovir cream and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. Antimicrob. Agents Chemother. 30, 196-198.
43. Spruance, S.L., Evans, T.G., McKeough, M.B., Thai, L., Araneo, B.A., Daynes, R.A., Mishkin, E.M., Abramovitz, A.S., 1995. Th1/Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res. 28, 39-55.
44. Spruance, S.L., Overall, J.C. Jr., Kern, E.R., Kreuger, G.C., Pliam, V., Miller, W., 1977. The natural history of recurrent herpes simplex labialis. New Engl. J. Med. 297, 69-75.
45. Stanberry, L.R., 1994. Animal models and HSV latency. Semin. Virol. 5, 213-219.
46. Steiner, L, Kennedy, P.G.E., 1995. Herpes simplex virus latent infection in the nervous system. J. Neurovirol. 1, 19-29.
47. Stevens, J.G., Cook, M.L., 1971. Latent herpes simplex virus in spinal ganglia of mice. Science 173, 843-847.
48. Wheeler, C.E. Jr., 1975. Pathogenesis of recurrent herpes simplex infections. J. Invest. Dermatol. 65, 341-346.
49. Yang, H., Datema, R., 1991. Prolonged and potent therapeutic and prophylactic effects of (S)-1-(3-hydroxy-2-phophonylmethoxypropyl) cytosine against herpes simplex virus type 2 infection in mice. Antimicrob. Agents Chemother. 35, 1596-1600.